CDK8 and prostate carcinoma: In addition to confirming the previously reported survival correlations for breast and prostate cancers [6,8], several new tumor types showed a correlation between higher CDK8 levels and shorter survival, suggesting that these cancers could be potential targets for CDK8/19 inhibitor therapy.